Softwr

Healthcare · head to head

Gleamer vs Paige

Gleamer logo

Gleamer

Healthcare

CE marked and FDA cleared imaging AI suite for bone trauma and chest, now owned by RadNet

From
On request
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Gleamer radNet, an imaging provider that competes with many independent Gleamer customers, now owns the company and also owns the competing DeepHealth AI portfolio, so roadmap and pricing priorities are an open question for non-RadNet buyers.; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Gleamer covers BoneView, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Gleamer and Paige actually diverge.

Attributes where Gleamer and Paige differ
AttributeGleamerPaige

Identical on both: starting price (On request), pricing model (quote), free tier (No), platforms (Web, Cloud, On-premise), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Gleamer

  • BoneView
  • ChestView
  • BoneAge
  • BoneMetrics
  • LungCT and BoneCT
  • BreastView
  • Pixyl.Neuro
  • Gleamer Copilot

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Gleamer

  • An emergency department where junior doctors read plain films before radiology review and missed fractures are a recurring incident themenot Paige
  • An urgent care network standardising musculoskeletal reading quality across sites with variable radiology covernot Paige
  • A paediatric service automating bone age assessment to remove a slow manual atlas comparisonnot Paige
  • An orthopaedic service that needs automated limb alignment and measurement before surgical planning rather than manual measurement on the workstationnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Gleamer
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Gleamer
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Gleamer
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Gleamer

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Gleamer

  • RadNet, an imaging provider that competes with many independent Gleamer customers, now owns the company and also owns the competing DeepHealth AI portfolio, so roadmap and pricing priorities are an open question for non-RadNet buyers.
  • The measured benefit is largest for less experienced readers, so a specialist musculoskeletal service will see far less improvement than the published reader studies suggest.
  • Cleared indications differ per module and per market, and the FDA cleared set is narrower than the CE marked European set, so an American buyer cannot rely on European reference sites.
  • Each additional module adds alert volume into the same worklist, and departments running several Gleamer algorithms report needing local threshold tuning to keep radiologist trust.
  • Pricing is per exam and not published, which makes budgeting difficult for an emergency department whose plain film volume swings seasonally.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Gleamer

On request
  • Gleamer Copilot$undefined/year
    • Priced per exam analysed or as an annual volume subscription
    • Modules licensed individually or bundled as Copilot
    • Cleared and CE marked indication differs per module and per market

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Gleamer if

  • You need boneview.
  • You work on Web, Cloud, On-premise.
  • You also want chestview.
Gleamer review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Gleamer or Paige better?
Neither clearly leads. Gleamer starts at On request and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Gleamer or Paige?
Gleamer starts at On request and Paige at On request.
Does Gleamer or Paige run on more platforms?
Both run on Web, Cloud, On-premise, so platform support will not decide this one for you.
What is Gleamer best used for?
Gleamer is most often used for an emergency department where junior doctors read plain films before radiology review and missed fractures are a recurring incident theme, an urgent care network standardising musculoskeletal reading quality across sites with variable radiology cover, a paediatric service automating bone age assessment to remove a slow manual atlas comparison, an orthopaedic service that needs automated limb alignment and measurement before surgical planning rather than manual measurement on the workstation. Of those, an emergency department where junior doctors read plain films before radiology review and missed fractures are a recurring incident theme and an urgent care network standardising musculoskeletal reading quality across sites with variable radiology cover are not what Paige is typically brought in for.
What can Gleamer do that Paige cannot?
Gleamer covers BoneView, ChestView, BoneAge, BoneMetrics. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Gleamer: Who owns Gleamer?

RadNet agreed to acquire Gleamer in February 2026 for around two hundred and fifteen million euros upfront. RadNet also owns DeepHealth, a competing AI portfolio.

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Gleamer: Is BoneView FDA cleared?

Yes, BoneView holds 510(k) clearance including for paediatric fracture detection, but the cleared finding set is narrower than the CE marked indication in Europe.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Gleamer: What does the evidence actually show?

Multi-reader studies reported improved reader sensitivity for fracture detection and fewer false negatives, with the gain concentrated among less experienced readers in emergency settings.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Gleamer: Can I buy just BoneView?

Yes, modules are licensed individually, though the commercial pitch is now the Copilot bundle across modalities.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Gleamer

More on Paige

Keep looking

Other head to heads